Trial Profile

Phase 1 study of AXN-2510 in patients with in relapsed/refractory solid tumors

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 09 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IMM-2510 (Primary)
Indications Solid tumours
Focus Adverse reactions

Most Recent Events

09 Jul 2025 New trial record
02 Jul 2025 According to an Instil Bio media release, the company expects to initiate a phase 1 trial of 2510 as monotherapy for patients with relapsed/refractory solid tumors before the end of 2025.
02 Jul 2025 According to an Instil Bio media release, the company announced the clearance of an Investigational New Drug (IND) application for AXN-2510 (2510) by the U.S. Food and Drug Administration.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com